Advanced search
1 file | 74.44 KB

Fatty acid composition of serum phospholipids in cystic fibrosis (CF) patients with or without CF related liver disease

Author
Organization
Abstract
Background: In cystic fibrosis (CF), changes in fatty acid (FA) composition of serum phospholipids (PL) and cell membranes can account, in part, for the inflammatory state of the disease. The severity of the genotype is known to correlate with the degree of FA changes. Liver diseases, such as cholestasis and cirrhosis are also known to influence FA status. Until now, there is no data on the influence of CF related liver disease (CFRLD) on the FA status of CF patients. The aim of this study was to evaluate, whether the presence of CFRLD influences FA status. Methods: A fasting blood sample for the determination of serum vitamin E and PL-FA composition was collected from 79 CF patients with stable pulmonary disease and under good control in our CF centre. Patients with CFRLD (n=13) were compared to CF patients with the same severity of genotype (n=66) but without CFRLD. Results: The CF patients with CFRLD had lower docosahexaenoic acid (DHA, 22:6n-3) and increased docosatetraenoic acid (22:4n-6). There were no significant differences in the precursors of these FAs. Conclusions: DHA concentration in patients with CFRLD is decreased more substantially compared with their genotype controls. The presence of CFRLD should be taken into account in future FA studies in CF patients. Clin Chem Lab Med 2010; 48:1751-5.
Keywords
PATTERN, CHOLESTEROL, LUNG, MECHANISMS, ABNORMALITIES, DEFICIENCY, PLASMA, METABOLISM, fatty acid, cystic fibrosis, liver disease, DOCOSAHEXAENOIC ACID, GENOTYPE

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 74.44 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Van Biervliet, Stephanie, Jean-Pierre Van Biervliet, Eddy Robberecht, and Armand Christophe. 2010. “Fatty Acid Composition of Serum Phospholipids in Cystic Fibrosis (CF) Patients with or Without CF Related Liver Disease.” Clinical Chemistry and Laboratory Medicine 48 (12): 1751–1755.
APA
Van Biervliet, Stephanie, Van Biervliet, J.-P., Robberecht, E., & Christophe, A. (2010). Fatty acid composition of serum phospholipids in cystic fibrosis (CF) patients with or without CF related liver disease. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 48(12), 1751–1755.
Vancouver
1.
Van Biervliet S, Van Biervliet J-P, Robberecht E, Christophe A. Fatty acid composition of serum phospholipids in cystic fibrosis (CF) patients with or without CF related liver disease. CLINICAL CHEMISTRY AND LABORATORY MEDICINE. 2010;48(12):1751–5.
MLA
Van Biervliet, Stephanie, Jean-Pierre Van Biervliet, Eddy Robberecht, et al. “Fatty Acid Composition of Serum Phospholipids in Cystic Fibrosis (CF) Patients with or Without CF Related Liver Disease.” CLINICAL CHEMISTRY AND LABORATORY MEDICINE 48.12 (2010): 1751–1755. Print.
@article{1147668,
  abstract     = {Background: In cystic fibrosis (CF), changes in fatty acid (FA) composition of serum phospholipids (PL) and cell membranes can account, in part, for the inflammatory state of the disease. The severity of the genotype is known to correlate with the degree of FA changes. Liver diseases, such as cholestasis and cirrhosis are also known to influence FA status. Until now, there is no data on the influence of CF related liver disease (CFRLD) on the FA status of CF patients. The aim of this study was to evaluate, whether the presence of CFRLD influences FA status. Methods: A fasting blood sample for the determination of serum vitamin E and PL-FA composition was collected from 79 CF patients with stable pulmonary disease and under good control in our CF centre. Patients with CFRLD (n=13) were compared to CF patients with the same severity of genotype (n=66) but without CFRLD. Results: The CF patients with CFRLD had lower docosahexaenoic acid (DHA, 22:6n-3) and increased docosatetraenoic acid (22:4n-6). There were no significant differences in the precursors of these FAs. Conclusions: DHA concentration in patients with CFRLD is decreased more substantially compared with their genotype controls. The presence of CFRLD should be taken into account in future FA studies in CF patients. Clin Chem Lab Med 2010; 48:1751-5.},
  author       = {Van Biervliet, Stephanie and Van Biervliet, Jean-Pierre and Robberecht, Eddy and Christophe, Armand},
  issn         = {1434-6621},
  journal      = {CLINICAL CHEMISTRY AND LABORATORY MEDICINE},
  keywords     = {PATTERN,CHOLESTEROL,LUNG,MECHANISMS,ABNORMALITIES,DEFICIENCY,PLASMA,METABOLISM,fatty acid,cystic fibrosis,liver disease,DOCOSAHEXAENOIC ACID,GENOTYPE},
  language     = {eng},
  number       = {12},
  pages        = {1751--1755},
  title        = {Fatty acid composition of serum phospholipids in cystic fibrosis (CF) patients with or without CF related liver disease},
  url          = {http://dx.doi.org/10.1515/CCLM.2010.336},
  volume       = {48},
  year         = {2010},
}

Altmetric
View in Altmetric
Web of Science
Times cited: